These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 33829355)
1. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Jeong H; Hong YS; Kim JE; Lim HS; Ahn JB; Shin SJ; Park YS; Kim ST; Han SW; Kim TY; Kim TW Invest New Drugs; 2021 Oct; 39(5):1335-1347. PubMed ID: 33829355 [TBL] [Abstract][Full Text] [Related]
2. Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. Oh DY; Kim TM; Han SW; Shin DY; Lee YG; Lee KW; Kim JH; Kim TY; Jang IJ; Lee JS; Bang YJ Cancer Res Treat; 2016 Jan; 48(1):28-36. PubMed ID: 25715767 [TBL] [Abstract][Full Text] [Related]
3. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Shin SJ; Ahn JB; Park KS; Lee YJ; Hong YS; Kim TW; Kim HR; Rha SY; Roh JK; Kim DH; Kim C; Chung HC Invest New Drugs; 2012 Apr; 30(2):672-80. PubMed ID: 21188464 [TBL] [Abstract][Full Text] [Related]
4. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952 [TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors. Kim HK; Kang JW; Park YW; Kim JY; Kim M; Kim SJ; Kim SM; Ho Ryu K; Yoon S; Kim Y; Cho JY; Lee KS; Yun T; Kim K; Kwak MH; Kim TS; Chung J; Park JW Pharmacol Res Perspect; 2020 Apr; 8(2):e00568. PubMed ID: 32162844 [TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118 [TBL] [Abstract][Full Text] [Related]
7. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136 [TBL] [Abstract][Full Text] [Related]
8. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cecchini M; Kortmansky JS; Cui C; Wei W; Thumar JR; Uboha NV; Hafez N; Lacy J; Fischbach NA; Sabbath KD; Gomez CM; Sporn JR; Stein S; Hochster HS Cancer; 2021 May; 127(9):1417-1424. PubMed ID: 33351187 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997 [TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719 [TBL] [Abstract][Full Text] [Related]
11. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. Chen EX; Jonker DJ; Siu LL; McKeever K; Keller D; Wells J; Hagerman L; Seymour L Invest New Drugs; 2016 Aug; 34(4):450-7. PubMed ID: 27075016 [TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639 [TBL] [Abstract][Full Text] [Related]
13. Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. Yuuki S; Komatsu Y; Fuse N; Kato T; Miyagishima T; Kudo M; Watanabe M; Tateyama M; Kunieda Y; Wakahama O; Sakata Y; Asaka M Clin Drug Investig; 2010; 30(4):243-9. PubMed ID: 20225907 [TBL] [Abstract][Full Text] [Related]
14. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang. Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Doi T; Yoshino T; Fuse N; Boku N; Yamazaki K; Koizumi W; Shimada K; Takinishi Y; Ohtsu A Invest New Drugs; 2015 Oct; 33(5):1068-77. PubMed ID: 26163340 [TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585 [TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. Sasaki Y; Hamaguchi T; Arai T; Goto A; Ura T; Muro K; Yamada Y; Shirao K; Shimada Y Anticancer Res; 2014 Apr; 34(4):2029-34. PubMed ID: 24692743 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Tewes M; Schleucher N; Achterrath W; Wilke HJ; Frings S; Seeber S; Harstrick A; Rustum YM; Vanhoefer U Ann Oncol; 2003 Sep; 14(9):1442-8. PubMed ID: 12954586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]